Hannah Valantine Sells 10,570 Shares of CareDx, Inc. (NASDAQ:CDNA) Stock

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Hannah Valantine sold 10,570 shares of the stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $19.16, for a total transaction of $202,521.20. Following the sale, the director now directly owns 38,994 shares in the company, valued at $747,125.04. This trade represents a 21.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

CareDx Stock Up 0.9%

CDNA traded up $0.18 during midday trading on Thursday, hitting $19.29. 709,532 shares of the company traded hands, compared to its average volume of 908,985. The firm has a market capitalization of $1.07 billion, a PE ratio of 16.77 and a beta of 2.18. The company's 50-day moving average is $17.62 and its 200 day moving average is $19.90. CareDx, Inc. has a 52 week low of $13.81 and a 52 week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The firm had revenue of $84.69 million for the quarter, compared to analysts' expectations of $84.56 million. During the same quarter in the prior year, the business earned ($0.03) EPS. The business's quarterly revenue was up 17.6% on a year-over-year basis. On average, sell-side analysts predict that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CDNA has been the topic of several recent analyst reports. Stephens reissued an "overweight" rating and set a $40.00 price objective on shares of CareDx in a research report on Monday, May 5th. The Goldman Sachs Group lowered their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. HC Wainwright restated a "neutral" rating and set a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. Finally, Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.

Hedge Funds Weigh In On CareDx

Several institutional investors have recently made changes to their positions in CDNA. Invesco Ltd. lifted its stake in shares of CareDx by 76.1% in the 1st quarter. Invesco Ltd. now owns 2,667,861 shares of the company's stock worth $47,355,000 after purchasing an additional 1,153,011 shares during the period. Divisadero Street Capital Management LP bought a new position in shares of CareDx in the 4th quarter worth approximately $15,239,000. Chevy Chase Trust Holdings LLC bought a new position in shares of CareDx in the 1st quarter worth approximately $9,502,000. Jacobs Levy Equity Management Inc. increased its holdings in CareDx by 52.6% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,243,580 shares of the company's stock worth $26,625,000 after acquiring an additional 428,864 shares in the last quarter. Finally, Bamco Inc. NY increased its holdings in CareDx by 17.6% in the 4th quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock worth $47,258,000 after acquiring an additional 330,627 shares in the last quarter.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.